Predictive And Prognostic Impact Of Ferroptosis-Related Genes Acsl4 And Gpx4 On Breast Cancer Treated With Neoadjuvant Chemotherapy

EBIOMEDICINE(2021)

引用 51|浏览45
暂无评分
摘要
Background: Recent evidence shows that inducing ferroptosis may improve efficacy of tumor therapy. How-ever, ferroptosis-related genes have been little studied in patients with breast cancer especially in the neoad-juvant setting. ACSL4 and GPX4 have been well established as the positive and negative regulator of ferroptosis, respectively. This study aimed to explore the predictive value of ACSL4 and GPX4 for patients with breast cancer administered neoadjuvant chemotherapy. Methods: This study included patients treated with paclitaxel-cisplatin-based neoadjuvant chemother-apy. Immunohistochemistry staining of ACSL4 and GPX4 was carried out on the core needle biopsy speci-mens. Logistic regression was performed to explore the predictive biomarkers of pathological complete response (pCR). Survival analyses were examined by log-rank test and Cox proportional hazard regression. Findings: A total of 199 patients were included for the analyses. Both ACSL4 expression and ACSL4/GPX4 com-bination status could serve as independent predictive factors for pCR. The interaction for pCR was observed between ACSL4 and clinical tumor stage. Besides, ACSL4 expression, GPX4 expression, and their combination status were independent prognostic factors for disease-free survival. Analyses of the Kaplan-Meier Plotter database suggested that higher ACSL4 expression is related to better overall survival, and higher GPX4 expression is related to better distant metastasis-free survival. Pathway analyses revealed that ACSL4 and GPX4 might function in crucial pathways including apoptosis, autophagy, cell adhesion, lipid metabolism, etc. Interpretation: This study revealed the critical value of ACSL4 and GPX4 serving as novel predictive and prog-nostic biomarkers for patients with breast cancer receiving neoadjuvant chemotherapy. It might be a novel strategy to induce ferroptosis to promote chemosensitivity. Future studies are required to elucidate the potential mechanisms. Funding: This work was supported by Shanghai Natural Science Foundation [grant number 19ZR1431100], Clinical Research Plan of Shanghai Hospital Development Center [grant numbers SHDC2020CR3003A, 16CR3065B, and 12016231], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Youth Medical Talents -Specialist Program [grant number 2018-15], Shanghai "Ris-ing Stars of Medical Talent" Youth Development Program for Outstanding Youth Medical Talents [grant number 2018-16], Shanghai Collaborative Innovation Center for Translational Medicine [grant number TM201908], Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University [grant num-bers YG2017QN49, ZH2018QNA 42, and YG2019QNA28], Nurturing Fund of Renji Hospital [grant numbers PYMDT-002, PY2018-IIC-01, PY2018-III-15, and PYIII20-09], Science and Technology Commission of Shanghai Municipality [grant numbers 20DZ2201600 and 15JC1402700], and Shanghai Municipal Key Clinical Specialty. (c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
更多
查看译文
关键词
Breast cancer, Neoadjuvant chemotherapy, Pathological complete response, Ferroptosis, ACSL4, GPX4
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要